You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
樂普生物子公司上海美雅珂在美啓動MRG004A一期臨牀試驗
格隆匯 09-30 10:49

2021年9月29日,荷蘭阿姆斯特丹-Synaffix B.V是一家專注於開發具有最佳治療指數的抗體偶聯平臺技術並推廣其使用在臨牀階段抗體偶聯藥物(ADC)上從而獲得商業化價值的生物技術公司。Synaffix B.V今日宣佈,其合作夥伴上海美雅珂已在美國啓動一項針對MRG004A的I期臨牀試驗。MRG004A是一種用於治療實體腫瘤的ADC藥物,也是全球第三個使用GlycoConnect ADC技術構建的ADC藥物進入臨牀研究。

2019年,Synaffix與中國生物技術公司上海美雅珂(現爲樂普生物科技股份有限公司的全資子公司)簽署了授權協議,上海美雅珂的管線包括多個臨牀階段的ADC新藥。MRG004A在美國第一例患者給藥這一重大進展爲Synaffix帶來了裏程碑式的付款。

MRG004A是一個靶向人組織因子(TF)的ADC藥物,通過GlycoConnect™定點偶聯技術完成構建。在臨牀前研究中,與傳統ADC技術相比,MRG004A顯著改善了血液循環中的穩定性,並增強了藥效和耐受性。

英文原文鏈接:

Third ADC with Synaffix's Technology Enters Clinical Development

https://www.prnewswire.com/news-releases/third-adc-with-synaffixs-technology-enters-clinical-development-301386989.html

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account